JP6584430B2 - 認知パフォーマンス、注意パフォーマンス、及び運動機能を改善するためのシチコリン投与 - Google Patents

認知パフォーマンス、注意パフォーマンス、及び運動機能を改善するためのシチコリン投与 Download PDF

Info

Publication number
JP6584430B2
JP6584430B2 JP2016564605A JP2016564605A JP6584430B2 JP 6584430 B2 JP6584430 B2 JP 6584430B2 JP 2016564605 A JP2016564605 A JP 2016564605A JP 2016564605 A JP2016564605 A JP 2016564605A JP 6584430 B2 JP6584430 B2 JP 6584430B2
Authority
JP
Japan
Prior art keywords
visit
day
group
difference
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016564605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520513A (ja
JP2017520513A5 (enExample
Inventor
ユーゲルン−トッド，デボラー
レンシャウ，ペリー
美穂 高田
美穂 高田
池田　武史
武史 池田
匡彦 森田
匡彦 森田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Hakko Bio Co Ltd
Original Assignee
Kyowa Hakko Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Bio Co Ltd filed Critical Kyowa Hakko Bio Co Ltd
Publication of JP2017520513A publication Critical patent/JP2017520513A/ja
Publication of JP2017520513A5 publication Critical patent/JP2017520513A5/ja
Application granted granted Critical
Publication of JP6584430B2 publication Critical patent/JP6584430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2016564605A 2014-04-30 2015-04-30 認知パフォーマンス、注意パフォーマンス、及び運動機能を改善するためのシチコリン投与 Active JP6584430B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461986502P 2014-04-30 2014-04-30
US61/986,502 2014-04-30
PCT/IB2015/053178 WO2015166463A1 (en) 2014-04-30 2015-04-30 Administration of citicoline to improve cognitive performance, attentional performance, and motor function

Publications (3)

Publication Number Publication Date
JP2017520513A JP2017520513A (ja) 2017-07-27
JP2017520513A5 JP2017520513A5 (enExample) 2018-03-08
JP6584430B2 true JP6584430B2 (ja) 2019-10-02

Family

ID=54358252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564605A Active JP6584430B2 (ja) 2014-04-30 2015-04-30 認知パフォーマンス、注意パフォーマンス、及び運動機能を改善するためのシチコリン投与

Country Status (8)

Country Link
US (2) US11583546B2 (enExample)
EP (1) EP3137067B1 (enExample)
JP (1) JP6584430B2 (enExample)
AU (1) AU2015254865B2 (enExample)
CA (1) CA2947252C (enExample)
ES (1) ES2915909T3 (enExample)
PL (1) PL3137067T3 (enExample)
WO (1) WO2015166463A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
US11583546B2 (en) 2014-04-30 2023-02-21 Kyowa Hakko Bio Co., Ltd. Administration of citicoline to improve cognitive performance, attentional performance, and motor function

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020198172A1 (en) * 1997-12-01 2002-12-26 Sandage Bobby W. Method of treating motor neuron diseases and demyelinating diseases with citicoline
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
EP1604671A4 (en) * 2003-02-26 2006-03-29 Kyowa Hakko Kogyo Kk MUSCLE TREATMENT AND MEANS FOR PREVENTING OR TREATING MUSCLE WEAKNESS
US20070248696A1 (en) * 2006-04-25 2007-10-25 Mind Sports Nutrition Inc. Composition and method for enhancing neuromuscular facilitation and cognitive functions
US20100041620A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods for improving frontal brain bioenergetic metabolism
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
EP2914270B1 (en) 2012-10-30 2022-01-12 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
US9883831B1 (en) * 2014-01-30 2018-02-06 Texas Health Biomedical Advancement Center, Inc. Digital medical evaluation and testing on a touch screen device
US11583546B2 (en) 2014-04-30 2023-02-21 Kyowa Hakko Bio Co., Ltd. Administration of citicoline to improve cognitive performance, attentional performance, and motor function

Also Published As

Publication number Publication date
US12115181B2 (en) 2024-10-15
CA2947252A1 (en) 2015-11-05
CA2947252C (en) 2022-05-10
US20230181614A1 (en) 2023-06-15
PL3137067T3 (pl) 2022-06-27
AU2015254865B2 (en) 2020-07-02
EP3137067A4 (en) 2017-12-27
JP2017520513A (ja) 2017-07-27
EP3137067A1 (en) 2017-03-08
NZ725643A (en) 2021-08-27
EP3137067B1 (en) 2022-05-04
WO2015166463A1 (en) 2015-11-05
AU2015254865A1 (en) 2016-11-24
ES2915909T3 (es) 2022-06-27
US11583546B2 (en) 2023-02-21
US20170049796A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
Goldberg et al. Subtle executive impairment in children with autism and children with ADHD
Hoffmann Higher cortical function deficits after stroke: an analysis of 1,000 patients from a dedicated cognitive stroke registry
Gardner et al. Use of check lists in assessing the statistical content of medical studies.
Dinn et al. Neurocognitive function in antisocial personality disorder
Lee et al. Testing the autogenous–reactive model of obsessions
Foster et al. Visual attention deficits in Alzheimer's disease: simple versus conjoined feature search.
US12115181B2 (en) Administration of citicoline to improve cognitive performance, attentional performance, and motor function
Parkin Survey of the success of communications between hospital staff and patients
Dirette et al. Patterns and antecedents of the development of self-awareness following traumatic brain injury: The importance of occupation
Hopkins et al. Neuropsychological functioning of dementia patients with psychosis
Allen et al. Hemispheric contributions to nonverbal abstract reasoning and problem solving.
Bauer et al. Evaluation of behavioral and cognitive changes: the mental status examination
Martínez-Delgado Standardisation of nursing care amongst patients in prison
Berch et al. Sex chromosome abnormalities and human behavior: psychological studies
Diaconu Emotion processing, psychophysiology and brain volume in maltreated youth. Markers of latent vulnerability and resilience
NZ725643B2 (en) Administration of citicoline to improve cognitive performance, attentional performance, and motor function
Júlio Everyday Executive Function in Parkinson and Huntington Disease: A Novel Ecological Approach
Hall et al. Journal of Psychological Inquiry
Burd Assessing HIV-related cognitive impairment among incarcerated chronic substance abusers
Donnelly The development of an instrument for assessing cognitive ability and screening for the cognitive decline associated with dementia in people with moderate to profound intellectual disability
Yeager Neuropsychological functioning and family environment of children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder/conduct disorder
Scott et al. A patient with bipolar illness and her neuropsychological signature
Mcguire Fear Conditioning and Extinction in Childhood Obsessive-Compulsive Disorder
Noutia ASSOCIATION BETWEEN SUBJECTIVELY EVALUATED COGNITION AND PERFORMANCE IN COMPUTERIZED COGNITION TESTING AMONG AGING WORKERS
Evans The development and pyschmetric properties of a decision making task for use in people with acquired brain injury

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190903

R150 Certificate of patent or registration of utility model

Ref document number: 6584430

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250